Cargando…
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
Regorafenib, an oral multikinase inhibitor, was approved in September 2012 by the US Food and Drug Administration for the treatment of patients with metastatic colorectal cancer progressing on standard therapies. Here, we describe the clinical history of a 63-year-old male patient who was treated wi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
S. Karger AG
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731102/ https://www.ncbi.nlm.nih.gov/pubmed/29279709 http://dx.doi.org/10.1159/000484401 |